Vectorite Biomedical News
News
0
Ticker
4170.TWO
ISIN
TW0004170006
Vectorite Biomedical Eulerpool News
Vectorite Biomedical Stock News
Vectorite Biomedical is being monitored by journalists and investors worldwide. We gather the latest Vectorite Biomedical news here.
Vectorite Biomedical Stock Press Releases
Vectorite Biomedical regularly publishes news on the company's website that are relevant for investors.
Vectorite Biomedical News 2026
This page contains all current news, analysis and press releases for Vectorite Biomedical stock (4170.TWO, ISIN: TW0004170006). This includes Eulerpool news, company analysis and official press releases. Data is updated regularly to provide investors with a complete overview of the latest developments at Vectorite Biomedical.
Vectorite Biomedical Stock
Vectorite Biomedical Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically.